Xu et al. demonstrated that the Lmdd-MPFG (LM) vaccine activates the NF-κB pathway in TAMs through the TLR2-MyD88 pathways (Chen Y. et al., 2012; Xu G. et al., 2020), which skewed the TAMs from M2 into M1, and skewed the TME cytokine profile of the TME toward an anti-tumor profile, this change restored the T cell reactivity to anti-PD-1 blockade (Xu G. et al., 2020). This evidence concerns the gene NFKB1 and neoplasm.